SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:oru-70214"
 

Sökning: id:"swepub:oai:DiVA.org:oru-70214" > A Swedish nationwid...

  • Fält, A.Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (författare)

A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of fingolimod (IMSE 2)

  • Artikel/kapitelEngelska2018

Förlag, utgivningsår, omfång ...

  • Sage Publications,2018
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:oru-70214
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-70214URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:vet swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Funding Agencies:Novartis  Biogenldec  Merck-Serono  TEVA  Sanofi-Genzyme  Bayer-Schering  Merck Serono  Sanofi Genzyme 
  • Background: Fingolimod (FGL) is an oral therapy for patients with relapsing-remitting multiple sclerosis (RRMS) and the efficacy has been shown in phase II and III studies. However; long-term surveillance and safety is important, therefore FGL is included in the Swedish “Immunomodulation and Multiple Sclerosis Epidemiology Study 2” (IMSE 2).Objective: To follow up the effectiveness and long-term safety of FGL in a real-world setting.Methods: Swedish MS patients are registered into the nationwide Swedish Neuro Registry (NeuroReg). IMSE 2 includes data of adverse events (AEs) and clinical measures; Extended Disability Status Scale (EDSS), Multiple Sclerosis Severity Scale (MSSS), Symbol Digit Modalities Test (SDMT), Multiple Sclerosis Impact Scale (MSIS-29), European Quality of Life - 5 Dimension Test (EQ-5D) and Visual Analogue Scale (VAS), obtained from NeuroReg.Results: From September 2011 until April 2018, 1617 patients (67% female; 91% RRMS) were included in IMSE 2. At treatment start 38 patients were ≤20 years (yr), 308 aged 21-30 yr and 1271 aged >30 yr. Mean treatment duration was 34 months. 852 patients were currently treated with FGL at cut-off date and 1230 patients had been treated for at least 12 months. In total, 39% switched treatment from interferons or glatiramer acetate, 26% from natalizumab and 5% from dimethyl fumarate or teriflunomide. 803 patients have discontinued FGL at some point, mainly due to lack of effect (43%) or AEs (34%), most patients switched to rituximab after FGL discontinuation. Relapses were reduced from 281 to 87/1000 patient years (PY) when comparing before and during FGL treatment. In patients aged ≤20 yr, 21-30 yr and >30 yr relapses were reduced from 694 to 144/1000 PY, 455 to 129/1000 PY and 258 to 77/1000 PY, respectively. After 12 months significant improvements were seen in EQ-5D (0.7 to 0.8, n=752), MSSS (3.1 to 2.9, n=410), MSIS-29 Physical (21.1 to 20.0 n=812), MSIS-29 Psychological (29.2 to 24.9, n=812), SDMT (54.3 to 57.0, n=751) and VAS (70.9 to 72.8, n=692). When analysing age groups separately significant improvements were seen in MSSS, SDMT, and MSIS-29 Psychological in patients aged 21-30 yr and >30 yr. EQ-5D, VAS and MSIS-29 Physical significantly improved in patients aged >30 yr.Conclusions: FGL is a generally well-tolerated drug that reduces the clinical activity in MS patients. NeuroReg functions well as a drug surveillance platform, enabling monitoring of long-term effectiveness and AEs.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Kågström, S.Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (författare)
  • Demirbüker, S. SaferDepartment of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (författare)
  • Hillert, J.Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (författare)
  • Nilsson, P.Department of Neurology, Lund University, Lund, Sweden (författare)
  • Dahle, C.Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden (författare)
  • Svenningsson, A.Department of Clinical Sciences, Danderyd Hospital, Stockholm, Sweden (författare)
  • Lycke, J.Department of Clinical Neuroscience and Rehabilitation, University of Gothenburg, Gothenburg, Sweden (författare)
  • Landtblom, A. -MDepartment of Neuroscience, Uppsala University, Uppsala, Sweden (författare)
  • Burman, J.Department of Neuroscience, Uppsala University, Uppsala, Sweden (författare)
  • Martin, C.Department of Clinical Sciences, Danderyd Hospital, Stockholm, Sweden (författare)
  • Sundström, P.Department of Clinical Neuroscience, Umeå University, Umeå, Sweden (författare)
  • Gunnarsson, Martin,1973-Örebro universitet,Institutionen för medicinska vetenskaper,Department of Neurology(Swepub:oru)mign (författare)
  • Piehl, F.Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (författare)
  • Olsson, T.Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (författare)
  • Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, SwedenDepartment of Neurology, Lund University, Lund, Sweden (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Multiple Sclerosis Journal: Sage Publications24:Suppl. 2, s. 696-6971352-45851477-0970

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy